Allogene Therapeutics, Inc. 8-K

What Happened

• Allogene Therapeutics (ALLO) announced on May 28, 2026 that its Board approved the appointment of Zachary Roberts, M.D., Ph.D., as President and Chief Executive Officer effective July 1, 2026. David Chang, M.D., Ph.D., will step down as President and CEO on June 30, 2026 and will continue on the Board as a non‑employee director.
• Dr. Roberts (age 48) currently serves as Executive Vice President, Research & Development (since Jan 2023) and Chief Medical Officer (since Apr 2023) and will continue as interim Chief Medical Officer after becoming CEO. The Board also appointed Dr. Roberts to the Board as a Class I director through the 2028 annual meeting.

Key Details

• Filing date: May 28, 2026; CEO change effective July 1, 2026 (Dr. Chang’s last day June 30, 2026).
• Compensation for Dr. Roberts (effective July 1, 2026): annual base salary $680,000 and an annual target cash incentive equal to 60% of base salary.
• Equity grants for Dr. Roberts: option to purchase 476,190 shares and 134,530 restricted stock units (RSUs). Option vests 25% after one year then monthly over the next 36 months; RSUs vest in four equal annual installments on July 20 each year following the grant year.
• Severance/change‑in‑control: Dr. Chang will be eligible for severance under the Company’s Severance Plan; Dr. Roberts will be entitled to severance and change‑in‑control benefits applicable to the CEO per the same Plan (details described in the Company’s April 30, 2026 proxy statement).

Why It Matters

• The company is replacing its CEO with an internal executive who keeps continuity in clinical and R&D leadership (Dr. Roberts will remain interim CMO). For investors, this signals a leadership transition with institutional knowledge retained rather than an outside hire.
• The disclosed pay package (salary, cash incentive target, significant equity awards and severance provisions) shows the Board’s incentives intended to align the new CEO with long‑term company performance. Investors should note the effective date (July 1, 2026), the equity vesting schedules, and the continued Board role and severance eligibility for Dr. Chang when assessing corporate governance and potential near‑term dilution or compensation-related expenses.